Opthea Ltd
ASX:OPT

Watchlist Manager
Opthea Ltd Logo
Opthea Ltd
ASX:OPT
Watchlist
Price: 0.6 AUD Market Closed
Market Cap: 820.8m AUD

Intrinsic Value

The intrinsic value of one OPT stock under the Base Case scenario is 0.23 AUD. Compared to the current market price of 0.6 AUD, Opthea Ltd is Overvalued by 61%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OPT Intrinsic Value
0.23 AUD
Overvaluation 61%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Opthea Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about OPT?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is OPT valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Opthea Ltd.

Explain Valuation
Compare OPT to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Opthea’s lead asset, OPT-302, is heavily reliant on successful Phase III trials in wet AMD; any negative clinical data or regulatory delays could derail the company’s primary growth driver and drain resources.

The company’s pipeline remains narrowly focused on retinal diseases, providing limited diversification; a single setback in OPT-302’s path to commercialization could disproportionately impact Opthea’s valuation and future prospects.

Ongoing development expenses and the likelihood of additional capital raises heighten the risk of shareholder dilution, especially as the firm invests substantially in late-stage clinical trials without parallel revenue streams to offset costs.

Bull Theses

OPT-302 has shown encouraging data in earlier clinical stages and, if Phase III results confirm superior efficacy, could tap into the multi-billion-dollar wet AMD market and drive significant revenue growth.

A successful pairing of OPT-302 with existing anti-VEGF treatments may enable Opthea to position the therapy as a differentiator in a competitive market, potentially boosting both market share and adoption rates by physicians.

Opthea’s ongoing collaborations and strong intellectual property protections around VEGF-C/D inhibition could secure a durable competitive edge and improve bargaining positions in future partnerships or licensing deals.

Show More Less
How do you feel about OPT?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Opthea Ltd

Current Assets 56.8m
Cash & Short-Term Investments 48.4m
Receivables 7.6m
Other Current Assets 750k
Current Liabilities 257.9m
Accounts Payable 9.7m
Accrued Liabilities 1.1m
Other Current Liabilities 247m
Efficiency

Free Cash Flow Analysis
Opthea Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Opthea Ltd

Revenue
25k USD
Operating Expenses
-155.9m USD
Operating Income
-155.9m USD
Other Expenses
-6.9m USD
Net Income
-162.8m USD
Fundamental Scores

OPT Profitability Score
Profitability Due Diligence

Opthea Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

53/100
Profitability
Score

Opthea Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

OPT Solvency Score
Solvency Due Diligence

Opthea Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Low D/E
Short-Term Solvency
Long-Term Solvency
47/100
Solvency
Score

Opthea Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OPT Price Targets Summary
Opthea Ltd

There are no price targets for OPT.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for OPT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one OPT stock?

The intrinsic value of one OPT stock under the Base Case scenario is 0.23 AUD.

Is OPT stock undervalued or overvalued?

Compared to the current market price of 0.6 AUD, Opthea Ltd is Overvalued by 61%.

Back to Top